Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trialRaches Ella, Siddhartha Dutta, Varsha Potdar et al.|The Lancet|2021Cited by 361
Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trialRaches Ella, Siddarth Reddy, William C. Blackwelder et al.|medRxiv|2021Cited by 80